The US Department of Health and Human Services will not take action against compounding pharmacies that make six peptides not yet approved for that use, giving them a temporary go-ahead while a formal rule change is worked on, NBC News reports.
The six substances are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, which are marketed online for faster healing, younger skin and longer life. None is approved by the Food and Drug Administration, and the agency's own scientists found too little evidence that they are safe and effective. Pharmacies must certify the identity and purity of the products and report side effects.
Health Secretary Robert F. Kennedy Jr has argued the move will draw people away from a grey market in products labelled "for research use only". A former FDA official said the agency was turning a blind eye to unproven drugs.
Source: NBC News
